No Data
No Data
Half-year report for the year 2024.
Summary of Half-Year Report in 2024.
BrightGene Gets Nod to Trial Salmeterol Fluticasone Inhalation Powder
Some Confidence Is Lacking In BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) As Shares Slide 29%
Brightgene Bio-Medical Technology Co., Ltd. (688166.SH): The clinical trial approval notice for Salmeterol Fluticasone Propionate Inhalation Powder has been obtained.
On August 1st, Gelunhui reported that Brightgene Bio-Medical Technology Co., Ltd. (688166.SH) announced that its holding subsidiary, Aitai Mei (Suzhou) Pharmaceutical Technology Co., Ltd. (referred to as “Aitai Mei”), has recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving Aitai Mei to conduct clinical trials of Salmeterol Fluticasone Inhalation Powder for adults and children with asthma.
Retail Investors Invested in BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) up 7.7% Last Week, Insiders Too Were Rewarded
No Data